A Phase 2 interventional study of STI571 in Systemic Sclerosis, Scleroderma, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.
Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 85th largest by enrollment of the 142 interventional ones that give a count, is one of 7 that started in 2008, is one of 54 in phase 2, and was the 25th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
Fate Therapeutics · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 42 more countries
Ages 18+
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 74 · Phase 3 17 · Phase 4 3
First in 1992; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 34 across the 142 interventional studies, 67 across the 22 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 165 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
15 of the studies in Scleroderma, Systemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT04380831City of Hope Medical CenterTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | 2026-12-22 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Scleroderma, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the efficacy and safety of STI571 for the treatment of fibrosis in participants with systemic sclerosis. Other purposes of the study were to investigate whether STI571 is effective in improving lung functions and other test results called biomarkers. Whether STI571 is well-absorbed in systemic sclerosis participants' gut was also investigated by testing the drug level in the blood (pharmacokinetics).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.
Drug: STI571
STI571 tablets taken orally once a day
Also known as: Gleevec, Glivec
Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis
The efficacy of oral STI571 in participants with systemic sclerosis is defined by an improvement in MRSS. Skin thickness was assessed clinically in each of 17 body areas and scored using a 0-3 scale, where 0= normal, 1= mild thickness, 2= moderate thickness, and 3= severe thickness (maximum score 51). A higher score indicates greater severity of the disease.
Time frame: Baseline, Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48/End of Study (EOS)
Number of Participants With Adverse Events (AE's) and Serious Adverse Events (SAE's)
An AE is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to the study drug. An SAE is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization, is medically significant, i.e., defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: Baseline to Week 48/EOS
Number of Participants With Non-response, Partial Response, Complete Response, and Remission Assessed by MRSS Values
The following MRSS categories were calculated for up to Week 48: Non-response: a reduction in MRSS \<25%, Partial response: a reduction in MRSS between 25-\<50%, Complete response: a reduction in MRSS between 50-\<80%, Remission: a reduction in MRSS ≥80%.
Time frame: Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48/End of Study (EOS)
This study was conducted at 7 centers in 5 countries from 02 January 2008 to 13 January 2010.
| Milestone | STI571 |
|---|---|
| Started | 27 |
| Completed | 13 |
| Not completed | 14 |
| Withdrew: Adverse event | 7 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Reason not specified | 4 |
The efficacy of oral STI571 in participants with systemic sclerosis is defined by an improvement in MRSS. Skin thickness was assessed clinically in each of 17 body areas and scored using a 0-3 scale, where 0= normal, 1= mild thickness, 2= moderate thickness, and 3= severe thickness (maximum score 51). A higher score indicates greater severity of the disease.
| units on a scale | STI571 |
|---|---|
| Baseline | 25.7 ± 5.83 |
| Week 2 | 6.58 ± 18.416 |
| Week 4 | 5.97 ± 17.382 |
| Week 6 | 8.34 ± 24.645 |
| Week 8 | 8.48 ± 27.096 |
| Week 12 | 3.34 ± 27.525 |
| Week 16 | 12.70 ± 28.399 |
| Week 20 | 12.41 ± 28.149 |
| Week 24 | 9.90 ± 23.675 |
| Week 28 | -3.17 ± 19.891 |
| Week 32 | -5.67 ± 18.013 |
| Week 36 | -12.61 ± 27.383 |
| Week 40 | -5.23 ± 27.506 |
| Week 44 | -13.57 ± 26.763 |
| Week 48/ EOS | -20.89 ± 24.946 |
An AE is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to the study drug. An SAE is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization, is medically significant, i.e., defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.
| Participants | STI571 |
|---|---|
| Participants Experiencing AE's | 27 |
| Participants Experiencing SAE's | 5 |
The following MRSS categories were calculated for up to Week 48: Non-response: a reduction in MRSS \<25%, Partial response: a reduction in MRSS between 25-\<50%, Complete response: a reduction in MRSS between 50-\<80%, Remission: a reduction in MRSS ≥80%.
| Participants | STI571 |
|---|---|
| Week 2 — Non-response | 27 |
| Week 2 — Partial Response | 0 |
| Week 2 — Complete Response | 0 |
| Week 2 — Remission | 0 |
| Week 4 — Non-response | 25 |
| Week 4 — Partial Response | 2 |
| Week 4 — Complete Response | 0 |
| Week 4 — Remission | 0 |
| Week 6 — Non-response | 24 |
| Week 6 — Partial Response | 2 |
| Week 6 — Complete Response | 1 |
| Week 6 — Remission | 0 |
| Week 8 — Non-response | 22 |
| Week 8 — Partial Response | 2 |
| Week 8 — Complete Response | 0 |
| Week 8 — Remission | 0 |
| Week 12 — Non-response | 15 |
| Week 12 — Partial Response | 3 |
| Week 12 — Complete Response | 0 |
| Week 12 — Remission | 0 |
| Week 16 — Non-response | 16 |
| Week 16 — Partial Response | 2 |
| Week 16 — Complete Response | 0 |
| Week 16 — Remission | 0 |
| Week 20 — Non-response | 16 |
| Week 20 — Partial Response | 2 |
| Week 20 — Complete Response | 0 |
| Week 20 — Remission | 0 |
| Week 24 — Non-response | 15 |
| Week 24 — Partial Response | 1 |
| Week 24 — Complete Response | 0 |
| Week 24 — Remission | 0 |
| Week 28 — Non-response | 13 |
| Week 28 — Partial Response | 1 |
| Week 28 — Complete Response | 0 |
| Week 28 — Remission | 0 |
| Week 32 — Non-response | 13 |
| Week 32 — Partial Response | 1 |
| Week 32 — Complete Response | 0 |
| Week 32 — Remission | 0 |
| Week 36 — Non-response | 9 |
| Week 36 — Partial Response | 3 |
| Week 36 — Complete Response | 0 |
| Week 36 — Remission | 0 |
| Week 40 — Non-response | 9 |
| Week 40 — Partial Response | 3 |
| Week 40 — Complete Response | 0 |
| Week 40 — Remission | 0 |
| Week 44 — Non-response | 8 |
| Week 44 — Partial Response | 5 |
| Week 44 — Complete Response | 0 |
| Week 44 — Remission | 0 |
| Week 48/EOS — Non-response | 5 |
| Week 48/EOS — Partial Response | 8 |
| Week 48/EOS — Complete Response | 0 |
| Week 48/EOS — Remission | 0 |
Collected over Baseline to Week 48/EOS. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ST1571 | 0/27 (0%) | 5/27 (18.5%) | 27/27 (100%) |
| Event | ST1571 |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/27 |
| Gastritis erosiveGastrointestinal disorders | 1/27 |
| NauseaGastrointestinal disorders | 1/27 |
| VomitingGastrointestinal disorders | 1/27 |
| Face oedemaGeneral disorders | 1/27 |
| Generalised oedemaGeneral disorders | 1/27 |
| Oedema peripheralGeneral disorders | 1/27 |
| Neutropenic infectionInfections and infestations | 1/27 |
| Upper respiratory tract infectionInfections and infestations | 1/27 |
| Viral infectionInfections and infestations | 1/27 |
| Event | ST1571 |
|---|---|
| Oedema peripheralGeneral disorders | 15/27 |
| NauseaGastrointestinal disorders | 14/27 |
| PruritusSkin and subcutaneous tissue disorders | 9/27 |
| DiarrhoeaGastrointestinal disorders | 7/27 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/27 |
| AnaemiaBlood and lymphatic system disorders | 6/27 |
| VomitingGastrointestinal disorders | 5/27 |
| Face oedemaGeneral disorders | 5/27 |
| FatigueGeneral disorders | 5/27 |
| HeadacheNervous system disorders | 5/27 |
Efficacy analysis set included all participants who received at least one dose of the study drug with at least one post-baseline measurement.
| Age, Continuous(years) | STI571 |
|---|---|
| Mean | 45.7 ± 11.99 |
| Sex: Female, Male(Participants) | STI571 |
|---|---|
| Female | 21 |
| Male | 6 |
Ran from Jan 2008 to primary completion in Jan 2010, 24 months.
Results were first posted in May 2021, 11 years 4 months after primary completion.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib